Senseonics Holdings, Inc. (SENS) Q3 2026 earnings review
Senseonics raises its sales outlook, but commercial costs widen losses
Senseonics, the maker of the one-year implantable Eversense glucose sensor, grew US sales fast while still losing over $30 million a quarter. Revenue rose 142% to $19.6 million — or about 101% by our math after stripping out the price boost from taking over sales from its former distributor. Chief executive Tim Goodnow raised the full-year sales outlook by $5 million, which by our math leaves fourth-quarter growth at 63%.
| Revenue | $19.6M +142% from a year ago (~101% excluding distributor change) |
|---|---|
| Gross margin | 61.7% 42.8% a year ago |
| Operating loss | $31.9M $19.6M loss a year ago |
| Full-year revenue outlook | Raised $5M middle of the range: $69M (+96% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because taking US sales in-house lifted gross margin to 62% and drove the largest outlook raise of the year. The company also began human trials on schedule for Freedom, its future sensor with no skin-worn transmitter. The bad news: European sales fell behind the original dollar plan, and a $32 million quarterly sales and overhead bill drained $16 million of cash.
The question now is whether US patient additions and one-year sensor renewals can shrink the cash burn before Senseonics needs to sell more shares. Either repeat orders lift revenue fast enough to cover the fixed sales force, or high marketing costs force another round of shareholder dilution. Fourth-quarter renewal sales and the full cash flow statement in the upcoming filing will tell.
🐂 Bull Case
US Sales and Nurse Network Beat the Plan
Senseonics makes Eversense 365, a blood-sugar sensor that a clinician places under the skin for a full year. At the start of 2026, the company took over US sales from its former distributor, Ascensia, which previously kept about 20% of revenue. Even stripping out that accounting boost, underlying sales roughly doubled from a year ago by our math.
- Total revenue: $19.6 million, up 141.6% from a year ago (about 101% excluding the distributor change by our math)
- US revenue: $16.8 million, up about 160% from a year ago on record unit shipments
- EON Care network (trained nurse inserters): passed 100 providers and handled over 40% of Q3 insertions, with the year-end goal raised from 100 to 120
- Active prescribing doctors: up about 90% from a year ago, down from 130% growth in Q2
Having trained nurses ready to insert the sensor matters because most primary-care doctors do not perform the procedure themselves. Chief commercial officer Brian Hansen said the growing nurse network lets the diabetes device maker expand advertising into new areas with an insertion option already in place. Because US demand ran ahead of plan, chief executive Tim Goodnow raised the full-year revenue outlook by $5 million at the middle of the range.
What to watch: fourth-quarter revenue, which the new full-year outlook puts at $22.2 million to $24.2 million by our math. Hitting that target will test whether the first patients who got the one-year sensor late last year come back for a replacement.
In-House Sales Lifted Gross Margin Past 61%
Keeping the full sale price instead of splitting it with a distributor has transformed the profit on each sensor sold. Gross margin — the share of sales left after the cost of making the sensors — reached 61.7% in the third quarter, up 18.9 percentage points from 42.8% a year ago. Cost of sales fell from 57.2% of revenue to 38.3%.
Goodnow said the improvement came from commercial infrastructure investments and higher volume, prompting the Maryland company to lift its full-year gross margin outlook to more than 60%, up from 58% to 61%. That marks the third raise this year after starting 2026 with a target near 50%, proving the one-year sensor can earn software-like manufacturing margins as volume grows.
What to watch: fourth-quarter gross margin, which needs to stay near 61% by our math for the full year to clear 60.5%. Holding that level as European sales grow will show that overseas pricing does not dilute US profitability.
Insulin Pump Deals and Freedom Trial Advance
Many Type 1 diabetes patients pair their glucose sensor with an automated insulin pump that adjusts insulin dosing automatically. Senseonics already connects Eversense 365 to the twiist pump from Sequel, and this quarter it partnered with Beta Bionics to link with the iLet Bionic Pancreas pump "to support continued growth into 2027", with a launch planned for the fourth quarter of 2026.
At the same time, the company began the first human trial of Freedom, an experimental one-year sensor designed to send readings straight to a phone "without any on-body component". Starting the human study on schedule keeps the 2028 launch goal alive, while adding a second insulin pump widens the pool of patients who can switch to Eversense next year.
What to watch: commercial launch of the iLet pump integration before year-end. Completing the technical work on time will show that partner delays will not slow 2027 patient additions.
🐻 Bear Case
Sales Costs Keep Quarterly Losses Above $30M
"Recent investments in commercial infrastructure are expanding patient access, supporting our growth and improving gross margins," chief executive Tim Goodnow said. While raising money earlier this year funded that expansion, absorbing the US and European sales teams has more than doubled overhead costs and kept the business deeply unprofitable.
- Selling, general and administrative expenses (sales and overhead): $32.3 million, up 110.7% from $15.3 million a year ago, or 164.9% of revenue
- Operating loss: $31.9 million, wider than the $19.6 million loss a year ago
- Cash and short-term investments: $126.6 million, down $16.4 million from $143.0 million in Q2
- Diluted share count: 65.7 million, up 46.2% from 45.0 million a year ago after equity offerings
Even though sales and overhead fell by 24.2 percentage points as a share of revenue compared with last year, the company still spent $1.65 on sales and overhead for every dollar of revenue. Gross profit rose by $8.6 million from a year ago, but operating expenses rose by $20.9 million, so revenue growth is not yet narrowing the dollar loss.
What to watch: the nine-month operating cash flow figure in the upcoming quarterly filing, alongside fourth-quarter sales and overhead costs. If quarterly cash burn does not slow from the first half's pace, the company will face pressure to sell more shares before its next-generation sensors launch.
European Sales Still Trail the Original Plan
Senseonics took over European commercial operations in June and is rolling out the one-year Eversense 365 sensor across Germany, Italy, Spain and Sweden. For the first half of the year, the company expected Europe to generate about 20% of full-year revenue as local hospital contracts transferred over.
In the third quarter, revenue outside the US reached $2.8 million, up about 65% from $1.7 million a year ago. However, the company lowered its full-year target: "Given the pace of U.S. outperformance, the Company now expects revenue outside the United States to represent approximately 15% of full-year 2026 revenue." By our math, 15% of the new $69 million outlook midpoint is $10.4 million, down from the $12.8 million implied by 20% of the old $64 million midpoint.
Blaming US strength hides a roughly $2.4 million cut to the overseas dollar forecast by our math, showing that European contract transfers are taking longer than planned. What to watch: fourth-quarter revenue outside the US, which needs to reach about $3.3 million by our math to hit the reduced 15% share.
Risks this quarter didn't answer
Four standing concerns around clinical timelines, patient retention, competition and debt rules received no numbers in the earnings release.
- Gemini clinical trial completion: the release notes ongoing trial spending for the self-powered Gemini sensor, but gives no update on whether the trial will finish by year-end for a first-quarter 2027 regulatory filing.
- First-year renewal rate and new patient additions: management did not disclose how many patients started on the sensor or what share of late-2025 patients ordered a second one-year unit.
- Competition from skin-worn sensors: no update on the share of new patients switching from rival Dexcom and Abbott sensors as those competitors extend their wear times.
- Debt covenants and operating cash flow: principal debt stayed at $55.0 million, but the full cash flow statement and minimum-cash covenant details await the quarterly Form 10-Q filing.
💲 Other KPIs
Up 50.4% from $7.8 million a year ago, and flat against $11.6 million in the second quarter. The company spent 59.6% of its revenue on research and clinical trials to test the Gemini and Freedom sensors, down from 95.8% of revenue a year ago as sales grew.
Money owed by customers and distributors rose 8.1% from $12.1 million at the end of 2025 by our math, while quarterly revenue grew 36.8% over the same span. Receivables from related parties — the old Ascensia arrangement — dropped from $5.3 million at year-end to zero as direct billing took over.
Stock of sensors and transmitters on hand stayed flat against $8.5 million in the second quarter and rose 25.9% from $6.7 million at the end of 2025. Inventory dropped to 43.1% of quarterly sales from 58.4% last quarter as record US shipments drew down stock.
🔮 Guidance
Raised. The middle of the full-year range moved up $5 million to $69 million, or 95.7% growth from 2025. By our math, that leaves $23.2 million for the fourth quarter — up 62.5% from a year ago, slowing from 141.6% in Q3 against a tougher reorder comparison. It is the third raise this year: +$2M, +$2M, +$5M.
Raised. The company lifted its full-year gross margin target to more than 60%, up from 58% to 61%. With gross margin at 60.3% across the first nine months, clearing 60.5% for the year requires fourth-quarter gross margin near 61.0% by our math, in line with Q3's 61.7%. It is the third raise since starting the year at roughly 50%.
❓ Key Questions
What percentage of late-2025 patients ordered a replacement sensor?
The first patients who received the one-year Eversense 365 sensor in late 2025 are now due for reinsertion. Management previously modelled a 75% first-year renewal rate, and fourth-quarter growth depends on those repeat orders.
Is the Gemini trial still on track for year-end completion?
Management previously targeted finishing the pivotal trial for the self-powered Gemini sensor by the end of 2026 and filing with the FDA in the first quarter of 2027, but the release gave no timeline update.
Why did full-year overseas sales expectations drop by $2.4 million?
Cutting the non-US share of 2026 revenue from 20% to 15% lowers implied overseas sales from $12.8 million to $10.4 million by our math. Investors need to know if European hospital tenders were delayed into 2027.
Did nine-month operating cash burn stay within the full-year plan?
The company used $62.2 million in operating cash during the first half against a full-year cash-use target of $110 million to $120 million. The press release did not include a cash flow statement.